Comparing Chemotherapy and Immune Therapy in Women Aged 18-75 With Recurrent Ovarian Clear Cell Carcinoma

What this Trial Is About

Researchers are comparing the effectiveness of different treatments for patients with relapsed or persistent ovarian clear cell carcinoma OCCC. This observational study aims to learn how well physicians choice of chemotherapy and immune checkpoint inhibitor ICI-based therapy work in real-world settings. It also compares these treatments to results from the INOVA clinical trial studying sintilimab plus bevacizumab combination therapy to see which approach may be more effective. The treatments being studied include two main groups one receiving chemotherapy chosen by their physician and another receiving ICI-based therapy. Researchers will collect and analyze de-identified electronic health records EHR data from patients treated with these therapies. The study does not assign treatments but observes outcomes based on treatments patients have already received or are receiving. Participants will be observed through their medical records to measure outcomes like tumor response rate, progression-free survival, time to response, duration of response, and disease control rate over about one year. This study mainly involves following patients health records without additional interventions or visits. The study is expected to end in May 2025 and includes female patients aged 18 to 75 years with a confirmed diagnosis of OCCC.

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary